A Phase 1/2, Global, Open-Label, Extension Study to Evaluate the Long-Term Safety and Clinical Activity of mRNA-3927 in Participants Previously Enrolled in the mRNA-3927-P101 Study
Clinical Trial Grant
Administered By
Pediatrics, Medical Genetics
Awarded By
Moderna Therapeutics, Inc.
Start Date
November 1, 2021
End Date
October 31, 2029
Administered By
Pediatrics, Medical Genetics
Awarded By
Moderna Therapeutics, Inc.
Start Date
November 1, 2021
End Date
October 31, 2029